APA (7th ed.) Citation

Giorgino, F., Taybani, Z., Cheng, A., Tebaibia, A., Anaforoglu, İ., Lauand, F., . . . Fonseca, V. (2025). A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: Soli de-escalation. Diabetes Research & Clinical Practice, 229, N.PAG. https://doi.org/10.1016/j.diabres.2025.112945

Chicago Style (17th ed.) Citation

Giorgino, Francesco, Zoltán Taybani, Alice Cheng, Amar Tebaibia, İnan Anaforoglu, Felipe Lauand, Soraly Servera, Xuan Li, and Vivian Fonseca. "A Real-world Study Assessing the Efficacy and Safety of Switching from Basal Bolus Insulin Therapy to Once Daily IGlarLixi in People with Type 2 Diabetes Mellitus: Soli De-escalation." Diabetes Research & Clinical Practice 229 (2025): N.PAG. https://doi.org/10.1016/j.diabres.2025.112945.

MLA (9th ed.) Citation

Giorgino, Francesco, et al. "A Real-world Study Assessing the Efficacy and Safety of Switching from Basal Bolus Insulin Therapy to Once Daily IGlarLixi in People with Type 2 Diabetes Mellitus: Soli De-escalation." Diabetes Research & Clinical Practice, vol. 229, 2025, p. N.PAG, https://doi.org/10.1016/j.diabres.2025.112945.